drugset / Trial / NCT00021723
Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease
Phase 2
Terminated
375 enrolled
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Wyeth is now a wholly owned subsidiary of Pfizer · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
A multi-center, double-blind, placebo-controlled out-patient, safety, tolerability, and pilot efficacy study of intramuscular AN-1792 in patients with mild to moderate Alzheimer's disease.
Timeline
- Start
- 2001-09
- Primary completion
- —
- Completion
- 2003-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AN-1792 | Unknown | — | Intramuscular |